Arrowhead Pharmaceuticals (ARWR) to Release Quarterly Earnings on Thursday

Arrowhead Pharmaceuticals (NASDAQ:ARWR) is scheduled to be releasing its earnings data after the market closes on Thursday, May 9th. Analysts expect Arrowhead Pharmaceuticals to post earnings of ($0.06) per share for the quarter. Parties interested in registering for the company’s conference call can do so using this link.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its quarterly earnings data on Tuesday, February 6th. The biotechnology company reported ($1.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.78) by ($0.46). The company had revenue of $3.55 million for the quarter, compared to analysts’ expectations of $35.60 million. Arrowhead Pharmaceuticals had a negative return on equity of 90.77% and a negative net margin of 163.32%. The company’s revenue for the quarter was down 94.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.39) EPS. On average, analysts expect Arrowhead Pharmaceuticals to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Arrowhead Pharmaceuticals Trading Up 2.9 %

Arrowhead Pharmaceuticals stock opened at $25.16 on Tuesday. The stock has a fifty day moving average price of $27.23 and a 200 day moving average price of $28.75. Arrowhead Pharmaceuticals has a 52 week low of $20.67 and a 52 week high of $41.36.

Insider Buying and Selling

In related news, Director Victoria Vakiener sold 1,799 shares of the firm’s stock in a transaction on Thursday, May 2nd. The stock was sold at an average price of $23.31, for a total transaction of $41,934.69. Following the transaction, the director now directly owns 30,205 shares in the company, valued at $704,078.55. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other Arrowhead Pharmaceuticals news, CFO Kenneth Allen Myszkowski sold 40,000 shares of the firm’s stock in a transaction that occurred on Wednesday, March 6th. The shares were sold at an average price of $35.19, for a total value of $1,407,600.00. Following the sale, the chief financial officer now owns 400,600 shares in the company, valued at $14,097,114. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Victoria Vakiener sold 1,799 shares of the stock in a transaction that occurred on Thursday, May 2nd. The stock was sold at an average price of $23.31, for a total value of $41,934.69. Following the completion of the transaction, the director now directly owns 30,205 shares of the company’s stock, valued at $704,078.55. The disclosure for this sale can be found here. Insiders own 4.50% of the company’s stock.

Wall Street Analysts Forecast Growth

ARWR has been the subject of a number of research analyst reports. Morgan Stanley upped their price objective on Arrowhead Pharmaceuticals from $34.00 to $36.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 7th. HC Wainwright restated a “buy” rating and issued a $90.00 price target on shares of Arrowhead Pharmaceuticals in a report on Thursday, February 8th. Citigroup boosted their price objective on shares of Arrowhead Pharmaceuticals from $33.00 to $34.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 7th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $50.00 target price on shares of Arrowhead Pharmaceuticals in a report on Wednesday, February 7th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, Arrowhead Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $50.80.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.